Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Solid Tumours 5Melanoma 5Neurofibromatosis 1 4Lung Neoplasms 4Rectal Neoplasms 3Neoplasm Metastasis 3Colorectal Neoplasms 3Colonic Neoplasms 3Breast Neoplasms 3Biliary Tract Neoplasms 3Neurofibroma, Plexiform 2Uveal Melanoma 1Solid Tumors 1Renal Insufficiency 1Primary Myelofibrosis 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Muscle Invasive Bladder Cancer 1Locally Advanced or Metastatic Solid Tumors 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Kidney Neoplasms 1Healthy Volunteers Pharmacokinetic Study 1Gallbladder Neoplasms 1Disease Progression 1Cholangiocarcinoma 1Advanced Non Small Cell Lung Cancer 1Advanced Cancer 1Adult Solid Neoplasm 1

Interventions

pembrolizumab 11Nivolumab 7Sunitinib 6Cyclophosphamide 6aldesleukin 5Sorafenib 5Everolimus 5temsirolimus 4belzutifan 4atezolizumab 4Ipilimumab 4fludarabine 3cabozantinib 3Interferon-alpha 3Gene Expression Profiling 3Fluorouracil 3Docetaxel 3Cetuximab 3Busulfan 3valspodar 2sargramostim 2perifosine 2pazopanib 2ixabepilone 2entinostat 2ciforadenant 2belinostat 2Thiotepa 2Temozolomide 2Sirolimus 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Kidney Neoplasms × AZD 6244 × Clear all
NCT00600496 2026-05-27

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

AstraZeneca

Phase 1 Completed
140 enrolled
BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Colonic Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡